CW7NPZZ
Systemic Nuclear Medicine Therapy Whole Body to None with None, Strontium 89 (Sr-89) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | W Anatomical Regions |
| Operation | 7 Systemic Nuclear Medicine Therapy |
| Body Part | N Whole Body |
| Approach | P Strontium 89 (Sr-89) |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of unsealed radioactive materials into the body for treatment
Procedure Overview
Systemic nuclear medicine therapy involves giving unsealed, or free-flowing, radioactive material into the body, typically by injection or swallowing a capsule, so that it travels through the bloodstream and concentrates in a specific tissue to deliver a therapeutic dose of radiation from within. Radioactive iodine used to treat an overactive thyroid or thyroid cancer is the most familiar example, but the same principle applies to newer radiopharmaceuticals used to treat certain prostate cancers, neuroendocrine tumors, or bone metastases.
Because the material is unsealed rather than contained in a shielded implant, it distributes through the body based on the biological behavior of the carrier molecule, concentrating where that molecule is naturally taken up. This lets clinicians target diseased tissue with radiation while limiting the dose delivered to unrelated organs, and it is generally given in a monitored setting because of the systemic radiation exposure involved.
Anatomy & Axis Detail
Whole Body
Whole body systemic nuclear medicine therapy describes radiopharmaceutical treatment intended to act broadly rather than on a single organ or region, as with radium-223 for diffuse osseous metastases from prostate cancer or iodine-131 MIBG therapy for disseminated neuroendocrine disease, where multiple skeletal or soft tissue sites throughout the body are treated simultaneously by a single systemic administration. Because the therapeutic effect depends on the agent's biodistribution rather than a localized delivery, dosimetry and blood count monitoring are important given the potential for marrow suppression when treatment is not confined to one area. This body part value is reserved for agents genuinely intended to treat disease wherever it resides in the body, rather than an agent that happens to circulate systemically but targets a single defined region. Documentation should describe the diffuse or multifocal disease process being addressed.
Radionuclide: Strontium 89 (Sr-89)
Strontium 89 (Sr-89) marks use of this radionuclide, a pure beta emitter administered systemically to palliate pain from widespread osteoblastic bone metastases by concentrating in areas of increased bone turnover. Unlike Samarium 153, it produces no meaningful gamma signal for imaging confirmation, making it a therapy-only agent distinguished from the diagnostic and mixed-use isotopes elsewhere in this axis.
Coding & Documentation
Documentation supporting a code here should confirm that the radioactive agent given was unsealed, meaning it was administered as a liquid, capsule, or infusion rather than a sealed source, and should name or describe the radiopharmaceutical used, since that determines the qualifier. The clinical indication, such as thyroid ablation or treatment of a hormone-producing tumor, helps confirm the therapeutic rather than diagnostic intent of the administration.
A frequent coding error is confusing a diagnostic tracer dose, which is coded to imaging or probe families, with a therapeutic dose of the same isotope, which belongs here; the intent and dose level documented by the physician distinguish the two. Coders should also avoid defaulting to a generic radioactive substance qualifier when the specific agent is identified in the record.
Commonly Confused With
This family is most often confused with Brachytherapy, since both deliver therapeutic radiation using radioactive material. The key difference is that brachytherapy uses a sealed source placed at or near a specific site, while systemic therapy uses an unsealed substance that travels throughout the body via the bloodstream or gastrointestinal tract. It can also be confused with the diagnostic nuclear medicine families, such as PET Imaging or Nonimaging Probe studies, which use similar radioactive agents but at tracer doses intended to gather information rather than to treat disease.